We've invested in groundbreaking technologies and platforms that aim
to deliver better solutions to our patients. These include
protein-based technologies that enhance the therapeutic potential of
antibodies by combining them with small molecule drugs.
Antibody Drug Conjugates (ADCs)
This technology platform
uses the targeting of an antibody to deliver a therapeutic agent. ADC
technology is more traditionally used in oncology however, by coupling
a highly potent immunomodulator to an anti-inflammatory monoclonal
antibody, it can be delivered to dysregulated immune cells with the
goal to turn down inflammation,
restore normal immune function and spare normal tissue. By combining
AbbVie’s expertise in discovering and developing specific monoclonal
antibodies with our experience in small molecule chemistry, AbbVie is
leading the field in applying ADC technology to immune-mediated diseases.
We've also concentrated our efforts
on boosting the therapeutic potential of specific small molecule
inhibitors by generating combinations of small molecule approaches in
fixed dose combinations.
Targeted drug delivery is a vital
avenue of our research because it can change the fundamental
way diseases are treated. We are exploring several new methods for